What are peptides? Are they steroids, and are they safe?
Reviewed 16 sourcesPublished by PepVault
Peptides are short chains of amino acids, not steroids. How they differ, which ones are FDA-approved, and how to judge the evidence behind any peptide.

- Last reviewed
- Sources
- 16
- Questions
- 7
- Compounds
- 6
The short answer
Peptides are short chains of amino acids, the building blocks of protein; the body makes many, insulin among them. They are not steroids, which are built on four fused carbon rings, though some peptides act on hormones. Whether one is safe depends on its evidence, so look for an FDA label first: approved peptides such as semaglutide have one; most research peptides have little human data.
Evidence: Definitions from the National Library of Medicine and federal regulations; safety told by evidence level, from FDA labels and FDA's own reviews; the library's counts as of November 2026.

What is a peptide?
A peptide is a chain of amino acids, the small molecules every protein is made from, joined end to end by a link chemists call a peptide bond1. Picture a string of beads, one bead per amino acid. The National Library of Medicine sorts them by length: chains of about 2 to 12 amino acids are oligopeptides, chains of about 13 or more are polypeptides, and proteins are larger versions that fold into complex shapes such as enzymes and receptors1.
Where a peptide ends and a protein begins is partly a matter of definition. FDA's rules for biological products set the line at 40: a chain of more than 40 amino acids with a set sequence counts as a protein3.
Peptides are not new to medicine. From insulin, almost a century ago, to 2021, more than 80 peptide drugs reached the market, for diabetes, cancer, osteoporosis, HIV infection, chronic pain and more13. Semaglutide, the medicine in Ozempic and Wegovy, is one: a peptide backbone made to act like GLP-1, a hormone the body makes, with a fatty chain that binds it to albumin in the blood, which is what makes it last5.
Peptide SkySee Semaglutide as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
Are peptides steroids?
No. The two are different kinds of molecule. A peptide is a chain of amino acids1. A steroid is built on a core of four fused carbon rings, the 17-carbon ring system shared by cholesterol, many hormones and bile acids2. Testosterone, the best-known steroid, is a small molecule with the formula C19H28O24; semaglutide is a chain about 14 times heavier45.
| What | Peptide | Steroid |
|---|---|---|
| Built from | Amino acids in a chain1 | Four fused carbon rings2 |
| Example | Semaglutide (Ozempic, Wegovy) | Testosterone |
| Molecular weight | 4,113.6 g/mol for semaglutide5; 4,813.5 for tirzepatide6 | 288.4 g/mol for testosterone4 |
| Body's own examples | Insulin13, GLP-15 | Cholesterol, many hormones, bile acids2 |
| US controlled-substance law | Not defined by the anabolic steroid rules | Anabolic steroids are Schedule III10 |

The law follows the chemistry. The Drug Enforcement Administration defines an anabolic steroid as a drug or hormonal substance chemically and pharmacologically related to testosterone9, and places anabolic steroids in Schedule III of the Controlled Substances Act10. A peptide is not chemically related to testosterone, so that definition does not reach it.
Why do some peptides get compared with steroids?
Because some of them work through hormones. Several peptides are signals that tell a gland to release its own hormone, and some of those hormones build tissue. Two approved examples show how:
- Tesamorelin copies the 44-amino-acid sequence of the hormone that tells the pituitary gland to release growth hormone, and growth hormone, its label notes, is both anabolic and lipolytic: it builds tissue and breaks down fat11.
- HCG, a polypeptide hormone, acts almost exactly like the body's luteinizing hormone: it stimulates cells in the testes to make androgens, the male sex hormones, testosterone among them12.

So a peptide can raise the body's own steroid hormones without being a steroid itself. That is where most of the mix-up comes from.
Is Ozempic a peptide?
Yes. Semaglutide, the medicine in Ozempic, is a peptide, and so is tirzepatide. Orforglipron, the medicine in the Foundayo pill, is not. The labels and the trials name what each one is made of:
| Brand | Medicine | A peptide? |
|---|---|---|
| Ozempic, Wegovy, Rybelsus | Semaglutide | Yes: a peptide backbone with a fatty chain5 |
| Mounjaro, Zepbound | Tirzepatide | Yes: a fatty-acid-modified peptide built on the GIP sequence67 |
| Foundayo | Orforglipron | No: a nonpeptide pill that acts on the same GLP-1 receptor8 |
What a medicine does and what it is made of are separate questions. Orforglipron switches on the same receptor as semaglutide, but it is a nonpeptide molecule, taken by mouth once a day8. Wegovy tablets show the reverse: semaglutide itself, a peptide, taken by mouth5.
Are peptides safe?
The word peptide says nothing about safety on its own; the evidence behind each one does. An approved peptide has been through FDA's review, in which the agency's physicians, statisticians, chemists and pharmacologists study the company's trial data and approve the drug only if its health benefits outweigh its known risks14. Its label then lists the side effects seen in the trials and how often each came56.
A research peptide has had no such review, and for many there is little human data to review. FDA's note on BPC-157, one of the most discussed, sits on its list of compounding substances whose nominations were withdrawn. It names a possible risk of immune reactions to compounded versions, and says the agency has no, or only limited, safety-related information for the routes proposed, so it lacks sufficient information to know whether it would cause harm in people15. That is mostly a statement about missing data, not a finding of harm. A label reading 'for research purposes' is not an approval either: FDA has warned companies that sold unapproved semaglutide, tirzepatide and retatrutide that way, and calls those products falsely labeled16.
Commonly reported: on the approved GLP-1 peptides, a smaller appetite and some nausea in the first weeks that eases with time; on research peptides such as BPC-157, easier joint and tendon pain, reports that have not yet been tested against a placebo.
On tirzepatide, for example, the label reports that most nausea, vomiting and diarrhea came while the dose was being raised and eased over time6. A reaction that is new and strong, such as swelling of the face or trouble breathing, is the time to get medical help at once.
How much evidence is behind the peptides people ask about?
PepVault's library has 101 entries, the peptides people ask about and the drugs they compare them with (about a dozen, such as orforglipron and MK-677, are small molecules, not peptides), and gives each one of three evidence levels. As of November 2026 they fall like this:
| Evidence level | What it means | Compounds | Examples |
|---|---|---|---|
| Established | Clinical trials or FDA-approved use exists | 27 | Semaglutide, tirzepatide, tesamorelin |
| Moderate | Animal studies and some human data | 33 | Ipamorelin, CJC-1295, Semax |
| Emerging | Mostly lab and animal research, limited human data | 41 | BPC-157, GHK-Cu, MOTS-c |

Established is not the same as approved. Of the 93 whose status we have read at FDA and ClinicalTrials.gov, 19 have a product FDA has approved, 2 had one that is now discontinued, 14 more have no approval but a registered company trial in phase 2 or phase 3, retatrutide among them, and 58 have neither. The 19 count oral semaglutide as its own entry and include two non-peptide drugs, orforglipron and clomiphene.
- By goal: the library groups its peptides by what people take them for, from weight loss to sleep.
- By status: the legal-status pages set each compound's FDA approval beside its standing in pharmacy compounding and sport.
- By brand: 21 approved brands, from Ozempic and Zepbound to Egrifta, each have a page of their label's facts.
- In the PepVault app, each compound in your protocol opens its library entry, evidence level included, and every side effect you log appears with its date and severity in the protocol report you can show a doctor.
How do you read the evidence on a peptide?
Six checks, in this order, sort most claims in a few minutes.
- Look the name up on Drugs@FDA or DailyMed. If it is approved, its label lists its uses and side effects, and that label is your best single source.
- If it is not approved, search ClinicalTrials.gov for human trials and note the phase: phase 3 trials are the large ones that come before an approval.
- Check who filed each trial record, since a record is only as solid as its sponsor.
- Read what each study was done in. A result in cells or in rats is a reason to study a peptide in people, not a result in people.
- Look for a control group. A study that compared the peptide with a placebo, with neither side knowing who got which, tells you far more than one that only followed people taking it.
- Read user reports as reports. They show what people notice, and they are where many trials begin, but they cannot separate the peptide's effect from time, rest and expectation.
Whether a peptide suits a given person, and at what dose, is a treatment decision for a doctor who knows their history. This guide explains what peptides are and how strong the evidence is; it is not a recommendation to take any of them.
Sources
- National Library of Medicine. Peptides. Medical Subject Headings (MeSH), descriptor 68010455. ncbi.nlm.nih.gov
- National Library of Medicine. Steroids. Medical Subject Headings (MeSH), descriptor 68013256. ncbi.nlm.nih.gov
- 21 CFR 600.3(h)(6), definition of a protein. Electronic Code of Federal Regulations. ecfr.gov
- PubChem. Testosterone (CID 6013). National Center for Biotechnology Information. pubchem.ncbi.nlm.nih.gov
- WEGOVY (semaglutide) prescribing information, section 11. DailyMed, Novo Nordisk, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) prescribing information, section 11. DailyMed, Eli Lilly, 2026. dailymed.nlm.nih.gov
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018. PubMed 30473097
- Wharton S et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023. PubMed 37351564
- 21 CFR 1300.01, definition of anabolic steroid. Electronic Code of Federal Regulations. ecfr.gov
- 21 CFR 1308.13(f), Schedule III: anabolic steroids. Electronic Code of Federal Regulations. ecfr.gov
- EGRIFTA SV (tesamorelin) prescribing information, sections 11 and 12.1. DailyMed, revised March 2024. dailymed.nlm.nih.gov
- NOVAREL (chorionic gonadotropin) prescribing information, Description and Clinical Pharmacology. DailyMed, 2025. dailymed.nlm.nih.gov
- Muttenthaler M et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021. PubMed 33536635
- U.S. Food and Drug Administration. Development & Approval Process | Drugs (content current as of August 8, 2022). fda.gov
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026). fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.